One important medical conditions in this country obesity has been an elusive target for researchers and drug companies. And now, since Orexigen the makers Contrave, have pulled the plug on the LIGHT clinical trial, the number of new diet drugs has droppe
Qsymia, the combination diet drug composed of phentermine and topiramate, was approved by the FDA in July of 2012. Now, the results of a study conducted between December 2007 and September 2008 and